Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase NA 1Phase 4 1Phase 1 1

Status

Recruiting 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Esophageal Squamous Cell Carcinoma 5Esophageal Neoplasms 1

Interventions

pembrolizumab 514Specimen Handling 384Carboplatin 372Magnetic Resonance Spectroscopy 337Cisplatin 327Nivolumab 301Cyclophosphamide 297Radiotherapy 255Paclitaxel 255Biopsy 237Gemcitabine 229Bevacizumab 212Dexamethasone 168durvalumab 162Oxaliplatin 159Capecitabine 154Rituximab 153Fluorouracil 148venetoclax 143atezolizumab 142Drug Therapy 140Docetaxel 140Etoposide 139Doxorubicin 132Ipilimumab 124Lenalidomide 119Radiosurgery 118Prednisone 116Leucovorin 112fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Esophagectomy × 1 year × Clear all
NCT07244978 2026-04-24

Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
49 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07519486 2026-04-15

INS-ESCC-CT

Sichuan University

Phase 2 Recruiting
118 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05659251 2025-12-02

Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Active not recruiting
48 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06576973 2025-12-02

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡